Hisashi Sakamaki
Overview
Explore the profile of Hisashi Sakamaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
235
Citations
2750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, et al.
Int J Hematol
. 2023 Feb;
117(5):694-705.
PMID: 36739328
Treatment-free remission (TFR) is a new goal for patients with chronic myeloid leukemia in chronic phase (CML-CP) with a sustained deep molecular response (DMR) to treatment with tyrosine kinase inhibitors...
2.
Nagata A, Otsuka Y, Konuma R, Adachi H, Wada A, Kishida Y, et al.
Leuk Lymphoma
. 2022 Sep;
63(13):3117-3127.
PMID: 36067521
Sarcopenia is a prognostic factor for cancer. Because creatinine is formed from creatine phosphate in muscle tissue, urinary creatinine excretion (UCE) serves as an index of muscle volume. However, as...
3.
Akiyama M, Inamoto K, Katayanagi N, Toya T, Najima Y, Kobayashi T, et al.
Rinsho Ketsueki
. 2022 Sep;
63(8):876-879.
PMID: 36058858
We examined the incidence and clinical features of thyroid dysfunction in 661 patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) in our hospital. At a median of 2.5 (1.0-11.3)...
4.
Mukae J, Sekiya N, Kato C, Sakai S, Nakashima S, Murakami D, et al.
Rinsho Ketsueki
. 2022 Sep;
63(8):849-854.
PMID: 36058853
A 60-year-old woman with myelodysplastic syndrome/myeloproliferative neoplasm-unclassifiable underwent unrelated bone marrow transplantation from a human leukocyte antigen (HLA) 8/8 allele-matched male donor. Neutrophil engraftment was achieved on day 29. Fluorescence...
5.
Kishida Y, Shingai N, Hara K, Yomota M, Kato C, Sakai S, et al.
Sci Rep
. 2022 Aug;
12(1):14155.
PMID: 35986078
Late-onset noninfectious pulmonary complications (LONIPC) are a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). However, the clinical impact of lung function deterioration itself in...
6.
Shirane S, Najima Y, Fukushima K, Sekiya N, Funata N, Kishida Y, et al.
J Infect Chemother
. 2022 Aug;
28(12):1658-1662.
PMID: 35963603
Invasive mucormycosis is a refractory fungal infection. Central nervous system (CNS) mucormycosis is a rare complication caused by infiltration from the paranasal sinuses or hematogenous dissemination. Here, we present a...
7.
Tanabe K, Najima Y, Inokuchi T, Endo M, Nishio Y, Sadato D, et al.
Rinsho Ketsueki
. 2022 Aug;
63(7):746-752.
PMID: 35922942
A 22-year-old man with a history of mediastinal germ cell tumor, which was diagnosed at age 20 and remained disease-free after chemotherapy, was diagnosed with acute myeloid leukemia (AML) M2...
8.
Kurosawa S, Toya T, Sadato D, Hishima T, Hirama C, Najima Y, et al.
EJHaem
. 2022 Jul;
2(4):854-860.
PMID: 35845190
A 58-year-old male was diagnosed with splenic B-cell lymphoma/leukemia, unclassifiable (SPLL-U). The lymphoma transformed into diffuse large B-cell lymphoma (DLBCL), and multidrug chemotherapy and autologous stem cell transplantation achieved complete...
9.
Kishida Y, Shingai N, Nakao S, Ishida S, Yamamoto K, Kurosawa S, et al.
Rinsho Ketsueki
. 2022 Jun;
63(5):347-352.
PMID: 35662156
A 31-year-old man underwent allogeneic bone marrow transplantation (BMT) for the treatment of transfusion-dependent aplastic anemia (AA) after conditioning with a regimen including fludarabine, cyclophosphamide, and antithymocyte globulin. The patient...
10.
Marumo A, Omori I, Tara S, Otsuka Y, Konuma R, Adachi H, et al.
Asia Pac J Clin Oncol
. 2022 Mar;
18(5):e507-e514.
PMID: 35289086
Cyclophosphamide (CY)-induced cardiotoxicity involves rare lethal complications. We previously reported the cardiac events of 811 allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients; 12 out of 811 recipients (1.5%) developed fatal...